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ABSTRACT

ARTICLE HISTORY

Background: De novo Donor Specific Antibodies (DSA) are considered as a risk factor for the kidney allograft outcomes in recipients after simultaneous liver–kidney transplantation (SLKT). We
hypothesized that length of hospital stay (LOS) might be associated with de novo DSA development of due to the increased likelihood of receiving blood transfusions with reduced immunosuppressive regimens.
Methods: This study is a single-center, retrospective cohort study consisting of 85 recipients
who underwent SLKT from 2009 to 2018 in our hospital. We divided the patients into two
groups according to LOS [long hospital stay (L) group (LOS >14 days) and short hospital stay (S)
group (LOS 14 days)]. Propensity score (PS) has been created using logistic regression to predict
LOS greater than median of 14 days. The association between the presence of de novo DSA and
LOS was assessed by logistic regression models adjusted for PS.
Results: The mean age at transplantation of the entire cohort was 55.5 ± 10.1 years. Sixty percent
of the recipients were male and Caucasian. Median LOS in (L) group was three-fold longer than
(S) group [L: median 30 days (IQR: 21–52), S: median 8.5 days (IQR: 7–11)]. Eight patients developed de novo DSA after SLKT (9.4%), all of them were in (L) group. Longer LOS was significantly
associated with higher risk of development of de novo DSA in unadjusted (ORþ each 5 days: 1.09,
95% CI:1.02–1.16) and PS adjusted (ORþ each 5 days: 1.11, 95% CI:1.02–1.21) analysis.
Conclusion: Longer hospitalization is significantly associated with the development of de novo
DSA in SLKT.
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Introduction
Post-transplant donor-specific antibodies (DSA), either
identified pre-transplant (persistent DSA) or newly
developed (de novo DSA) beyond the absorptive capacity conferred by allograft liver [1–4], present a risk factor for patient- and allograft kidney outcome after
simultaneous liver–kidney transplantation (SLKT) [5,6].
While the majority of pre-transplant DSA become
undetectable after liver transplantation alone (LTA) [7]
and after SLKT [8,9], about 10–20% of recipients
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develop de novo DSA after LTA and SLKT [5,6,10].
Currently, the risk factors associated with newly developed de novo DSA have not been well investigated in
SLKT. The identification of potentially modifiable risk
factors influencing de novo DSA development after
SLKT might have positive effects on patient and
graft survival.
Length of hospital stay (LOS) after surgery is one of
the relevant clinical outcomes measured in many clinical settings [11–13]. Longer LOS has been shown to be
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associated with patient characteristics such as age,
higher morbidity, worsened frailty, increased number
and severity of comorbidities and unfavorable clinical
outcomes and complications [11–16]. Previous studies
also showed longer LOS was associated with more
infectious complications; which could lead to decreased
use of immunosuppressive medications or larger
amount of blood product transfusions [14,15,17].
Infectious complications and blood transfusions have
also been identified as risk factors for longer LOS in
liver transplant recipients [18–20]. Infectious complications can cause cessation or reduction of immunosuppressive medications; while blood transfusions can
cause allo-sensitization [21,22]. Furthermore, early allograft liver dysfunction (EAD) was also identified as a risk
factor for longer LOS [23]. EAD grafts may lose the capacity to fully absorb existing pre-transplant DSA, which
might lead to persistent DSA after SLKT. Longer hospital
stay might serve as a surrogate marker for these sensitization events, in addition to demonstrating association with de novo DSA development after SLKT.
In this retrospective study, we hypothesized that
LOS is associated with a higher probability of de novo
DSA development after SLKT. We evaluated the association between LOS and de novo DSA development
using a single-center cohort in the modern immunosuppressant era.

Materials and methods
Cohort definition and data source
This is a single-center, retrospective cohort study. We
enrolled 85 consecutive recipients who underwent
SLKT from 1 April 2009 to 28 February 2018 at
Methodist University Hospital in Memphis, TN, USA.
Exclusion criteria being those who were less than
18 years old or equal, but no patients were excluded
from this study. Any information from recipients or
deceased donors, as well as immunologic information
were extracted from local electronic medical record
(EMR), from the UNOS database, and from our HLA
laboratory database until February 9th, 2019. We captured all data into a Research Electronic Data Capture
(REDCap) system, which is an electronic data capturing
tool hosted at the Center for Biomedical Informatics,
the University of Tennessee Health Science Center [24].
REDCap (Research Electronic Data Capture) is a secure,
web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking
data manipulation and export procedures; 3) automated export procedures for seamless data downloads
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to common statistical packages; and 4) procedures for
importing data from external sources.
The clinical and research activities being reported
are consistent with the Principles of the Declaration of
Istanbul as outlined in the ‘Declaration of Istanbul on
Organ Trafficking and Transplant Tourism’. All deceased
donated organs were procured based on SLKT allocation policy in Organ Procurement and Transplantation
Network (OPTN)/United Network for Organ Sharing
(UNOS) [25] and thus no organs were procured from
prisoners [26].
This study was approved by the Institutional Review
Committee of The University of Tennessee Health
Science Center (18-06146-XP). This is retrospective
observational data collection and waiver for the consent form from participated recipients was approved by
our IRB. Furthermore, this study did not need the consent from deceased donor either since this was not an
interventional study [27].

Immunosuppression protocol
The applied immunosuppression protocol was similar
for all patients regardless of pre-transplant sensitization
status [28]. As induction therapy, all patients received
intravenous methylprednisolone (500 mg) on day 0, and
rabbit anti-thymocyte globulin (1.5 mg/kg) on day 0
and again on post-operative day 2. Mycophenolate
mofetil (MMF) or equivalent mycophenolic acid was
started immediately post-operatively and continued
until month three. Tacrolimus was started after
improvement in kidney function, usually between
post-operative day 3–7, and target trough range was
6–8 ng/mL until 3 months post-transplantation and
3–5 ng/mL thereafter. No patients received pretransplant desensitization before SLKT. All patients
were maintained on a steroid-free protocol.

Exposure
The LOS was defined as the exposure in this study. LOS
was calculated as sum of the days from date of admission to date of discharge. LOS was divided into two
groups according to the median of 14 days. Long hospital stay group was defined as LOS greater than
14 days [(L) group] and short hospital stay group was
defined as LOS less than 14 days or equal [(S) group].
For the sensitivity analysis, the threshold of long LOS
was replaced with 28 days, which was two-times longer
compared to the main analysis and based on the previous literature [29,30].
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Covariates
We extracted data about recipients’ baseline characteristics including age, gender, race, body mass index
(BMI), marital status, insurance, cause of end-stage liver
disease (ESLD), cause of chronic kidney disease (CKD)/
end stage renal disease (ESRD), pre-SLKT dialysis information including length and type (maintenance dialysis
was defined as dialysis for 3 months; acute dialysis
initiation was defined as dialysis for <6 weeks; while
sub-acute dialysis was defined as dialysis for 6 weeks<3 months before transplantation), comorbid conditions (diabetes: DM and hypertension: HTN), the Model
for End-stage Liver Disease (MELD) score at SLKT, the
number of Human Leucocyte Antigen (HLA) mismatches, calculated panel reactive antibody (cPRA), and
cold-ischemic time (CIT) of donated kidney from the
above mentioned sources. As post-SLKT information,
first discharge destination, delayed allograft kidney
function (DGF), primary non-function (PNF) on allograft
kidney, death following transplant hospitalization. DGF
was defined as needs of dialysis within one-week post
SLKT [31] and PNF was defined as the condition on dialysis dependence after SLKT. Deceased donors’ information included age, sex, race, cause of death, history of
hypertension and diabetes, and expanded criteria
donor (ECD) status were also collected. All donations
occurred after brain death. There was only one recipient with missing value of CIT, thirteen recipients had
missing value of cPRA, and one recipient had missing
value of HLA mismatches. These missing values were
not imputed.

Outcomes
Primary outcome was incidence of development of de
novo DSA after SLKT. Furthermore, prevalence of posttransplant DSA (persistent or de novo DSA), was also
assessed as secondary outcome. Persistent DSA was
defined as DSA detected before and after SLKT, while
de novo DSA was defined as newly developed DSA following SLKT. We assessed the incidence of persistent
DSA or de novo DSA or in each patient after SLKT. HLA
specificities were identified using a solid phase single
antigen bead platform (SAB; One Lambda Inc, a division
of Thermo-Fisher, Canoga Park, CA, USA) combined
with Luminex xMAP technology (Luminex Corporation.,
Northbrook, IL, USA). Patients with any observed class
DSA were categorized as de novo DSA (þ), while those
negative for identified de novo DSA were classified de
novo DSA (). We defined post-DSA that has a mean
fluorescence intensity (MFI) value that is elevated compared to pre-transplant levels or has an MFI of greater

than 1000. The median days of measurement of DSA
from SLKT in both any post-transplant DSA and de novo
DSA were also calculated as sum of days. The DSA
measurements were performed as per clinical indication. The methodology of detecting DSA including the
decision of measurements, technical issues, and thresholds of DSA was not changed during the study period.

Statistical analysis
Baseline characteristics were described for the entire
cohort and for groups categorized based on the LOS
and presented as mean ± standard deviation (SD) or
median and interquartile range (IQR) for continuous
variables and percent for categorical variables as appropriate. Differences between groups were assessed by
student T-test or Mann-Whitney test for continuous variables and chi-square-test (or Fisher’s exact test) for categorical variables.
We calculated the propensity score (PS) for probability of long hospital stay in the main analysis (LOS
>14 days versus 14 days) and in the sensitivity analysis (LOS >28 days versus 28 days) using logistic
regression
model
(presented
in
Table
S1,
Supplementary material), including all available covariates without missing values for LOS, including age, gender, race, marital status, insurance, cause of ESLD,
diabetes, hypertension, BMI, blood type, MELD score,
first discharge destination, and DGF. The purpose of
this step was to be able to adjust for co-variates which
showed association with LOS. Because only 8 patients
developed de novo DSA, we were able to adjust for
only one variable in our adjusted logistic regression
analysis used for assessing association between LOS (as
exposure) and development of de novo DSA or any
post-transplant DSA (as outcomes). We then assessed
logistic regression analysis, unadjusted and PS score
adjusted, to calculate the relative risk (odds ratio) for
newly developing de novo DSA or any post-transplant DSA.
p values were two-sided and significance level was
set at less than .05 for all analyses. All analyses were
conducted using STATA Version 13 (STATA Corporation,
College Station, TX).

Results
Baseline characteristics
Table 1 shows the baseline characteristics of the entire
cohort for both (L) and (S) groups. The median age at
SLKT was 55.5 ± 10.1 years old and approximately 60%
of the patients were Caucasian males. The leading
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Table 1. Baseline characteristics of the entire cohort and divided by long and short hospital stay groups.
Baseline characteristics
Recipient information
Age, years, mean ± SD
Gender, male, n (%)
BMI, kg/m2, mean ± SD
Race, n (%)
African American
Caucasian
Other
Marital status, Married, n (%)
Insurance, n (%)
Private
Medicaid
Medicare
Presence of preexisting CKD, n (%)
Cause of CKD, n (%)
Hypertension
Diabetes
Glomerulonephritis
Cystic disease
Metabolic/inherited disease
Other/unknown
Dialysis status before SLKT, n (%)
Maintenance dialysis, n (%)
Sub-acute dialysis, n (%)
Acute dialysis initiation before SLKT, n (%)
Length of dialysis before SLKT (maintenance and sub-acute dialysis group),
months, median (IQR)
Length of acute dialysis before SLKT (acute dialysis group only), days, median (IQR)
Cause of ESKD (maintenance and sub-acute group), n (%)
Acute on CKD,
Same as CKD
Cause of ESLD, n (%)
HCV
Alcoholic hepatitis
HCV and Alcoholic hepatitis
NASH
Other
Comorbidity – diabetes, n (%)
Comorbidity – hypertension, n (%)
HLA mismatches locus A, n, mean ± SD
HLA mismatches locus B, n, mean ± SD
HLA mismatches locus DR, n, mean ± SD
Total HLA mismatches, n, mean ± SD
cPRA, %, median (IQR)
Cold ischemic time of donated kidney, minutes, mean ± SD
MELD score, mean ± SD
Donor information
Age, years, mean ± SD
Gender, male, n (%)
Donor Race, n (%)
Caucasian
African American
Hispanic
Donation after brain death, n (%)
Cause of death, n (%)
Anoxia
Cerebrovascular/stroke
Head trauma
Central nerve system tumor
Other
Comorbidity-diabetes, n (%)
Comorbidity-hypertension, n (%)
Expanded criteria donor, n (%)

Entire cohort,
N ¼ 85

Long hospital
stay group (L),
N ¼ 43

Short hospital
stay group (S),
N ¼ 42

55.5 ± 10.1
53 (62.4)
27.0 ± 6.4

56.7 ± 9.4
28 (65.1)
28.2 ± 7.2

54.4 ± 10.7
25 (59.5)
28.6 ± 5.6

22
51
12
52

(25.9)
(60.0)
(14.1)
(61.2)

11 (25.6)
26 (60.5)
6 (14.0)
27 (62.8)

11 (26.2)
25 (59.5)
6 (14.3)
25 (59.5)

31
6
48
74

(36.5)
(7.1)
(56.5)
(87.1)

16
4
23
32

15 (35.7)
2 (4.8)
25 (59.5)
42 (100)

(37.2)
(9.3)
(53.5)
(74.4)

8/74 (10.8)
14/74 (18.9)
4/74 (5.4)
3/74 (4.1)
2/74 (2.7)
43/74 (58.1)

4/32 (12.5)
6/32 (18.8)
2/32 (6.3)
0
0
20/32 (62.5)

4/42 (9.5)
8/42 (19.0)
2/42 (4.8)
3/42 (7.1)
2/42 (4.8)
23/42 (54.8)

38 (44.7)
9 (10.6)
16 (18.8)
8.9 (3.9, 36.8)

19 (44.2)
6 (14.0)
13 (30.2)
7.1 (3.3, 20.4)

19 (45.2)
3 (7.1)
3 (7.1)
13.0 (7.4, 44.6)

13.5 (6.5, 24.5)

12.0 (8.0, 24.0)

19.0 (5.0, 27.0)

12/47 (25.5)
35/47 (74.5)

8/25 (32.0)
17/25 (68.0)

4/22 (18.2)
18/22 (81.8)

24 (28.2)
22 (25.9)
3 (3.5)
16 (18.8)
20 (23.5)
35 (41.2)
61 (71.8)
1.6 ± 0.6
1.7 ± 0.5
1.5 ± 0.5
4.8 ± 1.0
0 (0, 8)
496.5 ± 114.6
28.3 ± 6.5

7 (16.3)
14 (32.6)
1 (2.3)
9 (20.9)
12 (27.9)
18 (41.9)
29 (67.4)
1.5 ± 0.7
1.7 ± 0.5
1.5 ± 0.6
4.8 ± 1.1
0 (0, 3.0)
514.3 ± 114.1
31.7 ± 6.3

17 (40.5)
8 (19.0)
2 (4.8)
7 (16.7)
8 (19.0)
17 (40.5)
32 (76.2)
1.5 ± 0.6
1.7 ± 0.5
1.6 ± 0.5
4.9 ± 0.9
0 (0, 13.0)
478.6 ± 113.6
24.9 ± 4.6

28.9 ± 11.1
47 (55.3)

29.2 ± 10.9
27 (62.8)

28.6 ± 11.4
20 (47.6)

65 (76.5)
18 (21.2)
2 (2.4)
85 (100)

36 (83.7)
7 (16.3)
0
43 (100)

29 (69.0)
11 (26.2)
2 (4.8
42 (100)

27
18
33
1
5
1
11
1

14 (32.6)
8 (18.6)
18 (41.9)
0
2 (4.7)
1 (2.3)
7 (16.3)
1 (2.3)

13
10
15
1
3

p Value
.292
.595
.827
.866

.783
.680

<.001
.647

.003

.077
.638
.278
.127

(31.8)
(21.2)
(38.8)
(1.2)
(5.9)
(1.2)
(12.9)
(1.2)

(31.0)
(23.8)
(35.7)
(2.4)
(7.1)
0
4 (9.5)
0

.897
.370
.859
.820
.535
.750
.866
.155
<.001
.793
.160
.163

–
.785

.320
.354
.320

BMI: Body mass index; CKD: Chronic kidney disease; cPRA: calculated panel reactive antibody; ESKD: End-stage kidney disease; ESLD: End-stage liver disease; HCV: Hepatitis C; HLA: Human Leukocyte Antigen; IQR: Interquartile range; MELD: Model of end-stage liver disease; NASH: Nonalcoholic steatohepatitis; SLKT: Simultaneous liver–kidney transplantation.

Compared between Long hospital stay group (L) group and short hospital stay group (L) groups. p values for continuous variables with mean ± SD are
result of t-test and with median (IQR) are result of Mann–Whitney test, and categorical variables are chi-square test.
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Table 2. Post-transplant characteristics of the entire cohort and divided by long and short hospital stay groups.

Length of stay for SLKT admission, days, me\dian (IQR)
Duration from admission to transplantation, days, median (IQR)
Duration from transplantation to discharge, days, median (IQR)
Delayed graft function (kidney), n (%)
Primary non-function (kidney), n (%)
Death during hospitalization, n (%)
First discharge destination, n (%)
Home
Home and taking health service
Rehabilitation hospital
Others
Incidence of developing of de novo DSA, n (%)
Duration from transplant to measurement of de novo DSA, days, median (IQR)
Prevalence of any post-transplant DSA, n (%)

Entire cohort,
N ¼ 85
15.0 (9.0, 30.0)
1.0 (1.0, 6.0)
11.0 (8.0, 21.0)
15 (17.6)
0
9 (10.6)

Long hospital
stay group, (L)
N ¼ 43
30.0 (21.0, 52.0)
6.0 (1.0, 16.0)
21.0 (12.0, 42.0)
12 (27.9)
0
7 (16.3)

41
22
12
10
8
53.0
12

12
13
10
8
8
53.0
11

(48.2)
(25.9)
(14.1)
(11.8)
(9.4)
(14.0, 280.5)
(14.1)

(27.9)
(30.2)
(23.3)
(18.6)
(18.6)
(14.0, 280.5)
(25.6)

Short hospital
stay group (S),
N ¼ 42
8.5 (7.0, 11.0)
0 (0, 1.0)
8.0 (6.0, 10.0)
3 (7.1)
0
2 (4.8)
29 (69.0)
9 (21.4)
2 (4.8)
2 (4.8)
0
N/A
1 (2.4)

p Value
<.001
<.001
<.001
.012
–
.084
.001

.003
–
.002

DSA: Donor specific antibody; IQR: Interquartile range; SLKT: Simultaneous liver–kidney transplantation.
Compared between long hospital stay and short hospital stay groups. p values for continuous variables with median (IQR) are result of Mann–Whitney
test and categorical variables are chi-square test.

causes of ESLD were hepatitis C and alcoholic hepatitis.
The patients in (L) group had significantly higher MELD
scores, prevalence of acute dialysis initiation shorter
length of dialysis before SLKT (maintenance and subacute dialysis) and higher prevalence of alcoholic hepatitis as a cause of ESLD compared with (S)
group patients.

Length of hospital stay and post-transplant events
Table 2 shows post-SLKT information of LOS, first discharge destination, and incidence of outcomes, DGF,
PNF, and death following SLKT hospitalization. The
median LOS of entire cohort was 15 days (IQR:
9–30 days) and duration from transplantation to discharge was median 11 days (IQR: 8–21 days). The
median LOS in (L) group was significantly longer than
that in (S) group [30 days (IQR: 21–52 days) and 8.5 days
(IQR: 7–11 days), p < .001], respectively. In (L) group,
incidence of returning to home as first discharge destination was significantly lower than in (S) group (27.9%
and 69.0%, respectively, p ¼ .001). No PNF was
observed; however, DGF of the allograft kidney was significantly higher in (L) group. Incidence of death during
SLKT hospitalization was higher in (L) group compared
to (S) group.

Developing of de novo DSA and prevalence of any
post-transplant DSA
Eight patients developed de novo DSA (9.4%) and 12
patients were identified with any post-transplant DSA
consisted of both persistent and de novo DSA (14.1%)
after SLKT (Figure 1). All patients who developed de
novo DSA and 11 out of 12 patients with any post-

Figure 1. Flow chart of patient selection and incidence and
prevalence of de novo DSA and persistent DSA. Abbreviations:
DSA: Donor-specific antibody; de novo DSA: newly developed
DSA; N: Number; SLKT: Simultaneous liver–kidney
transplantation.

transplant DSA were in (L) group. The median days
from SLKT was 22.0 days (IQR: 8.0–280.5 days) for measurement of any post-transplant DSA and 53.0 days was
(IQR: 14.0–280.5 days) for measurement of de novo DSA
(Table 2).
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Table 3. Probability of development of de-novo DSA and any post-transplant DSA using unadjusted and propensity score
adjusted logistic regression models.
Risk of de novo DSA
Un-adjusted
Length of hospital stay (each 5 days)
Adjusted
Length of hospital stay (each 5 days)
PS score

Risk of any post-transplant DSA

Odds ratio

95% CI

p value

Odds ratio

95% CI

p value

1.09

1.02–1.16

.010

1.08

1.02–1.15

.011

1.11
0.27

1.02–1.21
0.02–4.13

.014
.343

1.08
1.08

1.01–1.16
0.13–8.68

.028
.944

DSA: Donor specific antibody; PS: Propensity score; 95% CI: 95% confidence interval.

Probability of developing de novo DSA and any
post-transplant DSA
Longer LOS was significantly associated with higher
risk of development of de novo DSA in unadjusted
(ORþ each 5 days: 1.09, 95% CI: 1.02–1.16) and PS adjusted
(ORþ each 5 days: 1.11, 95% CI: 1.02–1.21) analysis (Table
3). Longer LOS was also significantly associated with
higher risk of prevalence of any post-transplant DSA
consisted of both persistent and de novo DSA in
unadjusted (ORþ each 5 days: 1.08, 95% CI: 1.02–1.15) and
PS adjusted (ORþ each 5 days: 1.08, 95% CI: 1.01–1.16) analysis (Table 3).

Probability of developing de novo DSA and any
post-transplant DSA in the sensitivity analysis
Longer LOS defined as >28 days was significantly associated with higher risk of development of de novo DSA
and prevalence of any post-transplant DSA consisted of
both persistent and de novo DSA in unadjusted and PS
adjusted analysis (Table S2, Supplementary material).

Discussion
In this single center, retrospective study, we found significant associations between longer hospitalization
and higher probability of both persistent post-transplant DSA and de novo DSA development after SLKT. In
addition, our study indicates that longer LOS occurred
more frequently in SLKT patients with higher MELD
scores and higher incidence of DGF in allograft kidney.
Furthermore, 30% of the patients in (L) group, compared to exact percentage in (S) group, were discharged to their home after SLKT. All of those who
developed de novo DSA had longer hospitalizations.
Our study implies that LOS might be a useful surrogate
marker of a higher probability for persistent DSA and
de novo DSA development. Patients, if not all, with longer hospitalization should be routinely screened for
DSA after SLKT. We believe this is the first report to
evaluate an association between the length of hospitalization and post-transplant DSA development in SLKT.

Sensitized status in SLKT has tended to be neglected
due to the absorptive capacity by allograft liver [1–4]. In
fact, sensitization before SLKT is not a contraindication
of transplantation from several clinical practice guidelines [32–34]. However, post-transplant DSA, especially
de novo ClassII DSA, has been thought to be a significant risk factor for patient-, allograft liver-, and allograft
kidney outcome [5]. No previous study has assessed the
risk factors of developing de novo DSA in SLKT,
although the potential for exposure to sensitizing
events might be expected to be higher in SLKT than
liver or kidney transplantation alone (LTA and KTA).
Although LTA patients typically do not undergo maintenance dialysis therapy before LTA, 30–50% of SLKT
candidates undergo dialysis therapy immediately prior
to SLKT [35,36]. We observed this finding in our cohort
as well. Simultaneous liver–kidney transplant patients
could be more fragile prior to transplantation and
require more blood transfusions peri-operatively compared to KTA patients [37]. Higher prevalence of maintenance dialysis therapy and history of blood
transfusions in SLKT patients has been associated with
sensitization [38–40], which leads to higher probability
of sensitization before and after transplantation compared to LTA and KTA patients.
We constructed a conceptual model of the assessed
relationship between LOS and DSA. We identified an
association between longer LOS and developing de
novo DSA. The relationship between assumptive exposures, (blood transfusions, infectious events) and EAD
and LOS has already been reported in other patient
cohorts [14,15] as well as recipients with LTA
[18–20,23]. We wanted to clarify a direct relationship
between presumptive exposures and de novo DSA
development. Our preliminary findings suggest LOS
might be a consequence of DGF on allograft kidney
secondary to persistent DSA or de novo DSA development or other potential intermediated mediators (indicator). Although we could not identify the exposure in
each patient, a relationship between presumptive exposures and de novo DSA development could exist in
accordance with this conceptual model.

46

M. YAZAWA ET AL.

Longer hospitalization also showed significant association with a higher probability of persistent or de
novo post-transplant DSA. In our cohort, 4 patients had
persistent DSA; 2 patients had both persistent and de
novo DSA after SLKT (Figure 1). Five of the six patients
with persistent DSA after SLKT, were in (L) group. Our
results suggest patients with pre-transplant DSA and
longer LOS should be routinely monitored for posttransplant DSA.
Several limitations should be noted with this study.
Although this is one of the largest SLKT cohorts studied
to date, our patient group was still small and had a relatively low number of events. Because this was a retrospective cohort study, we could not conclude causal
relationship between LOS and developing de novo DSA
despite the finding the median days of measurement of
DSA after SLKT was almost double compared to length
of hospital stay in (L) group. Furthermore, DSA measurement was indication based and not routine, which
might have caused observational bias. In this study, we
were not able to assess the pathophysiological role of
Class I and II DSA separately, as almost all of the
patients with post-transplant DSA had at least Class II
DSA (N ¼ 11/12) (Figure 1). Finally, the observed differences in clinical practices observed across different
transplant programs may lead to different definitions of
LOS. These differences could be the generalizability of
our findings. In fact, albeit LOS was replaced with
28 days or longer in our sensitivity analysis, LOS was still
significant risk factor for the developing of de novo DSA
and prevalence of any post-transplant DSA. Additional
prospective and larger studies that include protocol
DSA measurement are highly warranted.
Despite some limitations, our study has confirmed
several previous findings. LOS has been shown to be
predicted by factors such as ethnicity, discharge destination, and type of insurance [13]. In our study, (L) group
patients were more likely to be discharged to rehabilitation or discharged with home service than (S) group.
Despite have low event numbers, we were able to
adjust for these variables using a PS score. This is the
first report to identify LOS as a risk factor for de novo
DSA development in SLKT. Our results support the conclusion that DSA monitoring can be implemented into
clinical practice for SLKT patients.
In conclusion, longer hospitalization was significantly
associated with higher probability of persistent DSA
and de novo DSA development after SLKT. Although
longer hospitalization could be an indicator and not a
direct cause for de novo DSA development, DSA monitoring after LOS might be able to help providers
improve outcomes after SLKT. Additional prospective

and larger studies are highly warranted to identify
more modifiable and non-modifiable predictors for persistent and de novo DSA development following SLKT.
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